Kodiak Sciences: A Stellar Move

2026-02-03 07:48:12 ET

Shares of vision loss treatment concern Kodiak Sciences Inc. ( KOD ) have staged a massive rally off of their 52-week low set in April 2025, thanks to encouraging data from asset KSI-101 and its competitor. The IL-6/VEGF bispecific protein produced solid visual acuity gains in a Phase 1 study while tepid data from an IL-6 inhibitor validated its approach of reducing ocular fluid through VEGF inhibition. With registrational Phase 3 data anticipated from four trials in 2026 and two others in 2027, the recent rally and beneficial owner buying on Kodiak’s recent secondary merited a deeper dive for the first time since my last article on this name in early 2023. An analysis follows below....

Read the full article on Seeking Alpha

For further details see: